

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC IN RESPECT OF
THE COMPANY'S H SHARE FULL CIRCULATION APPLICATION

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Company has recently submitted a filing application to the China Securities Regulatory Commission (the “**CSRC**”) on behalf of certain shareholders of the Company regarding implementation of the full circulation of H shares of the Company (the “**H Share Full Circulation**”) for the conversion of an aggregate of 178,715,577 domestic shares and unlisted foreign shares of the Company into H shares of the Company and the listing thereof on the Stock Exchange (the “**Conversion and Listing**”). The Company is pleased to announce that the Company has received a Notice of the Full Circulation Registration of the Domestic Unlisted Shares of Jenscare Scientific Co., Ltd. (關於寧波健世科技股份有限公司境內未上市股份“全流通”備案通知書) dated March 7, 2024 (the “**Registration Notice**”) from the CSRC in respect of the Conversion and Listing.

As at the date of this announcement, details of the implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

The completion of the H Share Full Circulation and the Conversion and Listing is subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. Further announcement(s) will be made to disclose any material updates and progress in respect to the H Share Full Circulation and the Conversion and Listing in accordance with the Listing Rules and other applicable laws and regulations as and when appropriate.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, March 11, 2024

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.